Data from a prospective trial of HIFU-based hemiablation for localized prostate cancer

A new report provides data from a prospective, single-center, Phase II trial of high-intensity focused ultrasound (HIFU) in prostate cancer hemiablation as a form of focal therapy. The study was carried out in Belgium. … READ MORE …

One patient’s journey to active surveillance

A personal story on the MedPage Today web site this week tells a tale of how one 63-year-old professional journalist trod his own journey to management of his low-risk prostate cancer on active surveillance back in 2010. It may be instructive for many other patients newly diagnosed with low- and very low-risk prostate cancer.

CureTalk program on imaging and genomics with Dr. David Lee

Yesterday evening we held a CureTalk program on the roles of new imaging and genomic/genetic tests in the diagnosis, work-up, and prognosis of prostate cancer with Dr. David Lee of the University of Pennsylvania. … READ MORE …

What else was in the news today?

Today’s news contained items that run the spectrum from the clinical value of tomatoes and lycopene via the cardiovascular side effects of LHRH agonists and antagonists to the question of whether proton beam radiation therapy is really cost-effective. So here are the “news shorts” for the day: … READ MORE …

ED drugs and risk for prostate cancer recurrence? … NOT!

Back in February 2015 a group of German researchers published a study suggesting that there was a small but significantly increased risk of biochemical recurrence after prostate cancer treatment among men using drugs like sildenafil (Viagra) to recover/stimulate erectile function. … READ MORE …

What to do with a man with M0 or M1 disease who is progressing on treatment

Is the addition of enzalutamide (Xtandi) to an LHRH agonist now the appropriate standard of care for a man with M0 or M1 prostate cancer who starts to progress on treatment with an LHRH agonist alone? … READ MORE …

SBRT registries (and the interpretation of registry-based data)

Patient registries are potentially a rich source of information with which to evaluate outcomes. They often include patient characteristics, details of the therapies they received, and outcomes tracked over time. They also provide full population data of all patients treated at participating centers, and can provide very large amounts of data over time. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,369 other followers